MacroGenics, Inc. (NASDAQ:MGNX – Get Rating) – Investment analysts at SVB Leerink decreased their Q2 2023 EPS estimates for MacroGenics in a report issued on Tuesday, May 9th. SVB Leerink analyst J. Chang now expects that the biopharmaceutical company will earn ($0.71) per share for the quarter, down from their prior forecast of ($0.35). The […]
MacroGenics (NASDAQ:MGNX – Get Rating) had its price objective increased by equities research analysts at JMP Securities from $8.00 to $10.00 in a research note issued to investors on Thursday, The Fly reports. JMP Securities’ price target would indicate a potential upside of 38.70% from the stock’s previous close. Several other research firms have also […]
MacroGenics, Inc. (NASDAQ:MGNX – Get Rating) has received a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that […]
MacroGenics, Inc. (NASDAQ:MGNX – Get Rating) – Analysts at HC Wainwright lifted their Q1 2023 earnings per share estimates for MacroGenics in a research report issued to clients and investors on Monday, April 3rd. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company will post earnings of $1.44 per share for the quarter, […]
MacroGenics, Inc. (NASDAQ:MGNX – Get Rating) has earned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among […]